RecruitingPhase 2NCT05103904

Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant

Lenvatinib in Recurrent Hepatocellular Carcinoma After Liver Transplantation

Sponsor

Emory University

Enrollment

19 participants

Start Date

Apr 19, 2022

Study Type

INTERVENTIONAL

Conditions

Recurrent Hepatocellular Carcinoma

Summary

This phase II trial evaluates lenvatinib for the treatment of hepatocellular carcinoma (HCC) that has come back (recurrent) after a liver transplant. HCC is a cancer of the liver and is the second leading cause of cancer-related deaths in the world. Liver transplantation is a potentially curative treatment option for HCC, however, up to 20% of patients develop recurrent disease after liver transplantation and prognosis remains poor. Lenvatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Systemic treatments for HCC have not been studied in patients with recurrent HCC after liver transplantation, so there is no established therapy for these patients. This phase II trial evaluates lenvatinib for this purpose.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing lenvatinib — a targeted therapy that blocks tumor blood vessel growth — in people whose liver cancer (hepatocellular carcinoma) has returned after a liver transplant and cannot be surgically removed. **You may be eligible if...** - You are 18 years or older - You have liver cancer that has returned after a prior liver transplant - The cancer cannot be surgically removed - You are in reasonably good health (ECOG performance status 0–1) - Your liver is functioning adequately (Child-Pugh class A) - You have measurable disease trackable on scans - Your blood counts and organ function meet required minimums **You may NOT be eligible if...** - Your liver function is significantly impaired - You have not had a prior liver transplant - You are in poor general health - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERLaboratory Biomarker Analysis

Correlative studies

DRUGLenvatinib

Given PO

Locations(3)

University of Alabama at Birmingham

Birmingham, Alabama, United States

Mayo Clinic Arizona

Scottsdale, Arizona, United States

Emory University Hospital/Winship Cancer Institute

Atlanta, Georgia, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05103904

Related Trials

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

NCT0485111921 locations

Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC

NCT046151431 location

The Comparison of TACE-Lenvatinib With TACE-Lenvatinib-ablation for Intermediate Recurrent Hepatocellular Carcinoma

NCT066098501 location